SYK and Alzheimer disease: In addition, there are compounds with dual actions that are in preclinical stages for topical use in AD, such as a JAK3/tropomyosin receptor kinase A (TrkA) inhibitor, or have been used in early clinical trials such as the JAK/SYK inhibitor cerdulatinib (see below).